Novartis AG
NVS
111.2
USD+1.07
(+0.97%)Day's range
110.93
111.85
52 wk Range
96.06
120.92
Key ratios
Statements Highlights
| Period Ending | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | |
|---|---|---|---|---|---|---|
| Total Revenue | 49,898,000,000 | 52,877,000,000 | 51,828,000,000 | 46,660,000,000 | 51,722,000,000 | |
| Gross Profit | 34,777,000,000 | 37,010,000,000 | 36,342,000,000 | 34,188,000,000 | 38,895,000,000 | |
| Operating Income | 10,152,000,000 | 26,948,000,000 | 9,197,000,000 | 9,769,000,000 | 14,544,000,000 | |
| Net Income | 8,072,000,000 | 24,021,000,000 | 6,955,000,000 | 14,850,000,000 | 11,941,000,000 | |
| Total Assets | 132,059,000,000 | 131,795,000,000 | 117,453,000,000 | 99,945,000,000 | 102,246,000,000 | |
| Total Current Liabilities | 33,059,000,000 | 30,208,000,000 | 28,656,000,000 | 26,390,000,000 | 28,692,000,000 | |
| Total Equity | 56,666,000,000 | 67,822,000,000 | 59,423,000,000 | 46,750,000,000 | 44,126,000,000 | |
| Free Cash Flow | 11,065,000,000 | 12,100,000,000 | 11,565,000,000 | 11,705,000,000 | 13,805,000,000 | |
| Cash from Operations | 13,650,000,000 | 15,071,000,000 | 14,236,000,000 | 14,458,000,000 | 17,619,000,000 | |
| Cash from Investing | -13,182,000,000 | 4,208,000,000 | 1,468,000,000 | 5,596,000,000 | -7,513,000,000 | |
| Cash from Financing | -2,208,000,000 | -16,264,000,000 | -20,562,000,000 | -14,278,000,000 | -11,742,000,000 | |
| Net Change in Cash | -1,454,000,000 | 2,749,000,000 | -4,890,000,000 | 5,876,000,000 | -1,934,000,000 |
Dividends
Analyst Recomendations
Overall consensus
Buy